BIIB Q1 2020 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q1 2020 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$3.5B+1.3% YoY

Gross Profit

$3.1B87.1% margin

Operating Income

$1.8B51.5% margin

Net Income

$1.4B39.6% margin

EPS (Diluted)

$8.08

QoQ Revenue Growth

-3.7%

Cash Flow

Operating Cash Flow

$1.5B

Free Cash Flow

$1.3B

Stock-Based Comp.

$68M

Balance Sheet

Total Assets

$26.1B

Total Liabilities

$13.6B

Stockholders' Equity

$12.5B

Cash & Equivalents

$2.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.5B	$3.5B	+1.3%
Gross Profit	$3.1B	$2.9B	+6.7%
Operating Income	$1.8B	$1.5B	+21.1%
Net Income	$1.4B	$1.4B	-0.7%

Revenue Segments

MS Product Revenues

$2.1B58%

SPINRAZA

$565M15%

TYSABRI product

$522M14%

Interferon

$466M13%

Geographic Segments

UNITED STATES

$1.6B55%

Non-US

$1.3B45%